Japanese Encephalitis  Vaccines: WHO position paper  – February 2015.
D000818:Animals; D058345:Asymptomatic Infections / Q000453:epidemiology; D002522:Chlorocebus aethiops; D003362:Cost-Benefit Analysis; D004664:Encephalitis Virus, Japanese / Q000276:immunology / Q000472:pathogenicity; D004672:Encephalitis, Japanese / Q000175:diagnosis / Q000276:immunology / Q000517:prevention & control* / Q000635:transmission; D006801:Humans; D016867:Immunocompromised Host / Q000276:immunology; D022321:Japanese Encephalitis Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics / Q000276:immunology; D011159:Population Surveillance; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D014709:Vero Cells
D022321:Japanese Encephalitis Vaccines; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated